StockData
Talphera, Inc. logo

Talphera, Inc. (TLPH) company profile

TLPHNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 5/30
$0.86−0.05 (-4.98%)

Close on Nov 16, 2026Market cap $44.69MP/E –Yield –

About Talphera

Pharmaceutical Preparations, SIC 2834

The company is a specialty pharmaceutical business dedicated to developing and commercializing therapies for medically supervised healthcare settings. Its lead pipeline product is Niyad, a regional anticoagulant formulated with nafamostat for infusion into extracorporeal circuits during continuous renal replacement therapy. The enterprise is also investigating LTX-608, a direct intravenous nafamostat formulation targeting conditions such as disseminated intravascular coagulation, acute respiratory distress syndrome, acute pancreatitis, and viral infections. Intended customers and end users include hospital intensive care units, dialysis centers, and specialized clinical care providers.

Clinical development operations focus on the United States, where the business conducts registrational trials across hospital intensive care units. The company utilizes external contract manufacturing partners to produce its active drug substances and finished development formulations. Additionally, the corporate text references prior international commercial use of its core compound in Japan and South Korea, as well as European manufacturing facilities used by a third-party partner. The provided text does not state the company's specific headquarters location.

Summary of the business section of Talphera's latest annual report, written by StockData.

Company profile

Company

Legal name
Talphera, Inc.
Founded
2005
Headquarters
San Mateo, CA
Address
1850 Gateway Drive, Suite 175 94404
Phone
(650) 216-3500
Employees
12, Dec 31, 2025
Industry
Pharmaceutical Preparations
Incorporated in
Delaware
Fiscal year ends
December 31
Auditor
BPM LLP, Walnut Creek, California

Stock & identifiers

Ticker
TLPH
Former tickers
ACRX until Jan 9, 2024
Exchange
Nasdaq
IPO date
Feb 11, 2011
Shares outstanding
52M, Aug 6, 2026
Public float
$8.30M, Jun 30, 2025
Filer category
Non-accelerated filer<br>Smaller reporting company
Stock splits
1-for-20 reverse, Oct 26, 2022
SEC CIK
1427925
CUSIP
00444T209
ISIN
US00444T2096
FIGI
BBG0018YYFX7
Share class FIGI
BBG001TFZCK5
LEI
549300U8W781S4RBUE66
EIN
41-2193603

Executives and directors

Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years

NamePositionShares owned
Vincent J. AngottiCHIEF EXECUTIVE OFFICER, Director790,767
Shakil AslamChief Medical Officer76,542
Badri N. DasuChief Engineering Officer71,440
Raffi AsadorianChief Financial Officer85,879
Jill Marie BroadfootDirector13,647
Joseph TodiscoDirector11,497
Marina BozilenkoDirector14,147
Abhinav JainDirector12,412
Adrian AdamsDirector22,709
Mark A. WanDirector140,112
Stephen J. HoffmanDirector2,885,892

CEO pay and shareholder return

Pay versus performance table from the proxy statement

Fiscal yearCEO total payCEO pay actually paidOther executives (avg)Value of $100 investedPeer group
FY2025$1.12M$1.50M$691.08K$50–
FY2024$1.04M$844.56K$642.91K$23–
FY2023$1.21M$1.01M$778.44K$33–
FY2022$1.30M$692.48K$788.77K$20–

“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.

Executive compensation, fiscal 2025

Summary compensation table from the latest proxy statement

ExecutiveSalaryBonusStock awardsOption awardsOtherTotalvs. prior year
Vincent J. Angotti
Chief Executive Officer
$688.81K$206.64K$35.56K$172.26K$14.00K$1.12M+8%
Raffi Asadorian
Chief Financial Officer
$520.94K$145.86K$8.75K$37.76K$14.00K$727.31K+2%
Shakil Aslam
Chief Medical Officer
$473.20K$121.14K$8.75K$37.76K$14.00K$654.84K+24%

Stock and option awards are grant-date fair values, not realized pay. “Other” includes pension value changes and all other compensation. Source proxy statement.

IPO

From the final prospectus (Form 424B4) and the first day of trading

Offering

Type
Initial public offering
Final prospectus filed
Feb 11, 2011
Offer price
$5.00
Securities offered
8,000,000
Gross proceeds
$40.00M
Exchange
Nasdaq
First trading day
Feb 11, 2011
First-day close
$4.55-9.0%
Lock-up ends (est.)
Aug 10, 2011

“•The initial public offering price is $5.00 per share.”

Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.

Employees

Headcount reported in annual reports

“As of December 31, 2025, we employed 12 full-time employees, most of whom work out of our corporate offices in San Mateo, CA.”

Corporate history

Events identified from SEC filings

DateEventDetails
Mar 13, 2026Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 5, 2025Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 11, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Nov 29, 2024Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Dec 14, 2023Name changeName changed from ACELRX PHARMACEUTICALS INC to Talphera, Inc.
Oct 20, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Oct 5, 2023Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 28, 2023Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Apr 7, 2023Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Jul 28, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jun 2, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
May 9, 2022Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jan 12, 2022Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Dec 3, 2021Listing noticeNotice of delisting or failure to satisfy a listing rule (8-K Item 3.01)
Jul 29, 2021Auditor changeChange in certifying accountant (8-K Item 4.01)
Apr 6, 2020MergerRegistration of securities for a merger or exchange offer (S-4)
Sep 21, 2015Acquisition / saleCompletion of acquisition or disposition of assets (8-K Item 2.01)
Aug 21, 2015Auditor changeChange in certifying accountant (8-K Item 4.01)
Feb 11, 2011IPOInitial public offering priced (424B4 prospectus)
Feb 1, 2011ListingRegistration of securities on an exchange (Form 8-A)

See a number that looks wrong?